The role of Napsin-A and Desmocollin-3 in classifying poorly differentiating non-small cell lung carcinoma

Ezzat, Noha; Tahoun, Neveen

doi:10.1016/j.jnci.2015.11.002

Cited by 7 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Desmocollin-3 as a diagnostic biomarker: a. Squamous NSCLC: DSC3 is used as a diagnostic biomarker to differentiate Squamous NSCLC from adenocarcinoma of lung [35][36][37][38][39][40][41][42]. DSC3 is more specific for squamous NSCLC compared to p63 as p63 is also expressed in Adenocarcinoma.…”

Section: Lmentioning

confidence: 99%

Desmocollin-3 and Cancer

Khamar¹

2017

BJSTR

View full text Add to dashboard Cite

Section: Lmentioning

confidence: 99%

Desmocollin-3 and Cancer

Khamar¹

2017

BJSTR

View full text Add to dashboard Cite

“…The choice of antibody clone and the cut off value for positive staining are of great importance for the evaluation of IHC stains. In the literature for Napsin A the cutoff value ranged from 1% to 10% (6,10) . In our study we used 5% as cut off value for Napsin A.…”

Section: Discussionmentioning

confidence: 99%

“…Hematoxylin and Eosin (H & E) stained slides from both biopsy and resection specimens were examined to revise tumor histology. Tumors were classified into SCC if they showed intercellular bridges or keratinization, AD if they showed glandular formation or mucin production, adeno-squamous if they showed a mixture of SCC and AD features, and LCC if lacked glandular or squamous differentiation (10) .…”

Section: Histopathological Evaluationmentioning

confidence: 99%

Diagnostic Value of Napsin A in Small Biopsy of Non-Small Cell Lung Carcinoma

Samir

Osman

El-Deftar

2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Accurate sub-classification of non-small cell lung carcinoma (NSCLC) is crucial for the targeted therapy. In lung cancer most of tumors are un-respectable at diagnosis and small biopsy or cytological specimen is commonly the only available material for histopathology diagnosis. Although most of NSCLC can be diagnosed by routine stains, however diagnosis of poorly differentiated or undifferentiated tumors in small biopsy is challenging. Objective: To evaluate the diagnostic value of Napsin A immunohistochemical (IHC) marker in NSCLC small biopsy. Materials and Methods: Forty-six cases of primary NSCLC diagnosed by biopsy with subsequent resection were enrolled in this study. Subtyping of tumors was done according to 2015 World Health Organization criteria. IHC expression of Napsin A was assessed for all the cases. For large cell carcinoma (LCC) cases, Thyroid Transcription Factor 1 (TTF-1) and P63 expression were also tested. Markers expression was correlated with the histological diagnosis of the tumor. Sensitivity, specificity, positive, negative predictive values, and total accuracy of the markers were calculated. Result: In NSCLC cases, the diagnostic sensitivity and specificity of Napsin A were 85.2% and 75% (respectively) with a PPV of 85.2%, NPV of 75.0% and 81.4% accuracy. In LCC cases TTF1 sensitivity was 57.1% and specificity 100%, PPV 100%, NPV 14.3%, accuracy 60.0%. In LCC P63 marker had a diagnostic sensitivity, specificity, PPV, NPV and accuracy of 100%, 85.7%, and 33.3%, 100.0% and 86.7% respectively. Expression of both Napsin A and TTF 1 in LCC cases raised the accuracy to 86.7%. Conclusions: In small biopsy specimens Napsin A can subtype NSCLC with high sensitivity and moderate specificity. Additions of TTF-1/p63 IHC markers can further enhance the accuracy.

show abstract

“…Among the established markers for AD, napsin A expression has been reported in 59-87% of pulmonary ADs, which is in line with our results. It seems to be a moderately sensitive (64-79% to 87%) and highly specific (94-100%) marker for lung ADs [20,24,25,26], but its expression is associated with higher differentiation of the tumor [22,27].…”

Section: Discussionmentioning

confidence: 99%

High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material

Szade¹,

Majewska²,

Żaczek³

et al. 2019

pjp

View full text Add to dashboard Cite

The most recent classification of the lung cancer expanded the diagnostic criteria of its histological subtypes and included its immunophenotypic profile. We performed the study to compare the reliability of selected markers in high-grade nonsmall cell lung carcinoma (NSCLC) in the oligobiopsies with the matched postoperative samples. We evaluated expression of p40, p63, TTF1, cytokeratin 5/6, cytokeratin 7, napsin A, desmoglein 3, desmocollin 3 and mucin secretion as detected by mucicarmine staining. The study cohort included 123 cases of poorly-differentiated NSCLC. The tissue oligobiopsy material was available in 38 cases. Tissue microarrays (TMAs) from all postoperative cases were constructed. Comparing the immunophenotype between postsurgical samples and oligobiopsies we found an almost perfect agreement for most of performed IHC reactions. The highest concordance of results was found for desmoglein 3, CK7, and p40, whereas the lowest-for desmocollin 3. Immunoprofile of the oligobiopsies corresponded well to that in the resection specimens. The most useful markers in poorly differentiated ADs are: TTF1 and napsin A, and for non-keratinizing SCCs: p40, p63, CK5/6 and desmoglein 3.

show abstract

The role of Napsin-A and Desmocollin-3 in classifying poorly differentiating non-small cell lung carcinoma

Abstract: Napsin-A, and Desmocollin-3 were sensitive and specific markers for the diagnosis of AC and SCC, respectively. Both markers allowed classification of 54/60 cases into either AC or SCC.

Cited by 7 publications

References 30 publications

Desmocollin-3 and Cancer

Desmocollin-3 and Cancer

Diagnostic Value of Napsin A in Small Biopsy of Non-Small Cell Lung Carcinoma

High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material

Contact Info

Product

Resources

About